Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
28.63M
Enterprise Value
7.25M
Income
-34.90M
Sales
0.00M
Book/sh
1.88
Cash/sh
2.35
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
31
IPO
Oct 28, 2010
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.74
P/C
1.39
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
2.76
Current Ratio
2.76
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-9.33
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
67.06% 56.72%
Sales past 3/5Y
- -
EPS Y/Y TTM
87.83%
Sales Y/Y TTM
-
EPS Q/Q
67.06%
Sales Q/Q
-
Insider Own
0.15%
Insider Trans
0.00%
Inst Own
12.63%
Inst Trans
0.33%
ROA
-154.34%
ROE
-203.63%
ROIC
-212.82%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-3.90%
SMA50
-11.37%
SMA200
-12.47%
Trades
Shs Outstand
8.73M
Shs Float
8.72M
52W High
13.09 -74.94%
52W Low
2.60 26.15%
Volatility
7.61% 8.34%
ATR (14)
0.28
RSI (14)
44.09
Beta
1.23
Rel Volume
0.00
Avg Volume
256.00K
Volume
0
Perf Week
-8.64%
Perf Month
-5.20%
Perf Quarter
-16.54%
Perf Half Y
-15.46%
Perf YTD
-53.87%
Perf Year
-57.35%
Perf 3Y
-99.50%
Perf 5Y
-99.78%
Perf 10Y
-99.94%
Prev Close
3.28
Price
3.28
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$150.00
Implied Upside
+4,473.2%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Feb 14, 2022Initiated
HH.C. Wainwright
Buy$25+662.2%
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
M.D.Dr. William V. Williams FCPA
C.A.Mr. Gadi Levin B.Com.
Chief Scientific OfficerDr. Miguel A. Lopez-Lago Ph.D.
M.P.H.Dr. Giuseppe Del Priore M.D.
M.D.Dr. Charles Louis Wiseman FACP